Home Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
 

Keywords :   


Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today

2014-11-17 14:30:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. Data are Embargoed by American Heart Association until 10:45 AM CT Today WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today. About Merck Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data today american primary

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11adabat
27.11slp
27.11Nana
27.11
27.11
27.11Daiwa LABRAX ags87lml
27.11 Disney100 & Disney 100
27.11
More »